Event Details:
CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months
Date and Time: September 15, 2020 at 15:00 – 16:00 CET
Presenters: Craig Cook CEO, Antti Vuolanto COO, Henri Huttunen CSO
The webinar will commence with a presentation by the Company, followed by a live Q&A session.
To join the Webinar: Register for Webinar here
About the presenters:
Craig Cook, CEO
A medical doctor with an MBA from the London Business School, Dr. Cook brings more than 20 years of experience in the international pharmaceutical and biotechnology sectors. His career has realised increasingly senior roles in drug development and commercialization at major life science companies such as Eli Lilly, Johnson & Johnson, Novartis and EMD Serono, as well as entrepreneurial success in several healthcare initiatives. Most recently Dr. Cook was CEO of Midatech Pharma PLC a dual Nasdaq and AIM listed biotech company, before deciding to join Herantis Pharma. He has worked across several therapeutic areas including neurology, immunology, and oncology.
Antti Vuolanto, COO
Antti Vuolanto, DSc, joined Herantis Pharma Plc in February 2018. He has vast experience in biological drug development, gene therapy, and in-vitro diagnostics. Previously he has served as COO at Valo Therapeutics, as Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that was merged with Targovax in 2015. He has also held senior management positions at other biotech companies. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.
Henri Huttunen, CSO
Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO until February 2010. Dr. Huttunen is currently the Chief Scientific Officer of Herantis, and has also served as member of the Board of Directors until April 2014. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and more than 20 years of experience in neuroscience research.
For more information, please contact:
Julie Silber/Gabriela Urquilla
JG-IR
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com